Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.2 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Remedium Lifecare Limited has completed the allotment of 47,87,90,132 rights equity shares at Re. 1 per share (face value Re. 1), as approved by the Board on May 22, 2025. The total rights issue size was up to Rs. 4,919.04 lakhs, based on the Letter of Offer dated April 24, 2025. Post-allotment, the paid-up equity share capital has risen from Rs. 40.32 crore (40.32 crore shares) to Rs. 88.20 crore (88.20 crore shares), more than doubling the share count. The basis of allotment was finalized with BSE as the Designated Stock Exchange. Note: The filing was sourced under the name Supha Pharmachem Ltd, but the actual filer is Remedium Lifecare Limited.
The share count has more than doubled, which will dilute EPS and typically pressure the share price on a per-share basis. Shareholders who did not subscribe to the rights issue will see their proportionate ownership reduce unless they participated.